Skip to main content

#151666

Anti-cROS [4-6G]

Cat. #151666

Anti-cROS [4-6G]

Cat. #: 151666

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: cROS

Class: Monoclonal

Application: IHC ; IF ; IP ; Fn ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Al Charest

Institute: Tufts University

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-cROS [4-6G]
  • Research fields: Cancer;Cell signaling and signal transduction;Genetics
  • Clone: 4-6G
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: IHC ; IF ; IP ; Fn ; WB
  • Description: Monoclonal antibody directed against cROS, a proto-oncogene with therapeutic target potential.
  • Immunogen: Extracellular portion of ROS amino acid 1-285 fused to Fc, transiently expressed in 293 cells and purified using PtnA column chromatography.
  • Immunogen uniprot id: P08922
  • Isotype: IgG1
  • Myeloma used: Sp2/0-Ag14
  • Recommended controls: Cells transiently expressing human cROS, mouse cells expressing human cROS

Target Details

  • Target: cROS
  • Tissue cell line specificity: Cells transiently expressing human cROS, mouse cells expressing human cROS
  • Target background: c-ROS is a proto-oncogene tyrosine kinase, that is highly-expressed in a variety of tumour cell lines and belongs to the sevenless subfamily of tyrosine kinase insulin receptor genes. It is a type I integral membrane protein and may function as a growth or differentiation factor receptor. The c-ROS gene promoter region has been identified and characterized and it has been shown that the ectopic expression of c-ROS in tumours is tied to hypomethylation of a CpG island in the c-ROS promoter. Tumours with ROS1 mutations are typically responsive to small molecule tyrosine kinase inhibitors.

Applications

  • Application: IHC ; IF ; IP ; Fn ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
  • Shipping conditions: Dry ice

References

  • Fei et al. 2019. Biosci Rep. 39(6):. PMID: 31138757.
  • Zhang et al. 2019. Int J Biol Sci. 15(7):1460-1471. PMID: 31337976.
  • Shih et al. 2017. Oncogene. 36(47):6542-6554. PMID: 28759046.
  • Deng et al. 2014. Int J Mol Med. 34(3):661-8. PMID: 24968753.
  • Charest et al. 2003. Proc Natl Acad Sci U S A. 100(3):916-21. PMID: 12538861.
  • Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.